# US 10,441,627 B2 · Method of treating prader-willi syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,627 B2
- Document ID: US10441627B2
- Status: Granted
- Kind: B2
- Application number: 15/510,781
- Filed: 2015-09-14
- Published: 2017-11-16
- Granted: 2019-10-15
- Earliest claimed: 2014-09-19
- Assignees: Ferring B.V.
- Applicants: Ferring B.V.
- Inventors: Pascal Danglas; Michael Reidy; Paul Korner; Sudarkodi Alagarsamy
- Web page: https://patentgrep.com/patent/US10441627B2

## CPC

- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 9/0043: {Nose}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 5/10: of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating Prader-Willi Syndrome, comprising administering intranasally to a human patient in need thereof an effective amount of a composition comprising carbetocin or a pharmaceutically acceptable salt thereof, wherein the method comprises administering a daily dose of the carbetocin or pharmaceutically acceptable salt thereof of from about 5.76 mg to about 28.8 mg.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition is administered three times a day.

### Claim 3 (depends on 2)

The method of claim 2, wherein each administration delivers about 10 mg of the carbetocin or pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 2)

The method of claim 2, wherein each administration is performed before a meal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method comprises administering a daily dose of the carbetocin or pharmaceutically acceptable salt thereof of from about 10 mg to about 28.8 mg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method comprises administering a daily dose of about 28.8 mg of carbetocin or pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is administered as an intranasal spray.

### Claim 8 (depends on 3)

The method of claim 3, wherein the composition is administered as an intranasal spray.

### Claim 9 (depends on 7)

The method of claim 7, wherein the composition comprises the carbetocin or pharmaceutically acceptable salt thereof dissolved in an aqueous solution.

### Claim 10 (depends on 7)

The method of claim 7, wherein the method comprises administering a daily dose of 28.8 mg of carbetocin.

### Claim 11 (depends on 7)

The method of claim 7, wherein the method comprises administering a daily dose of about 10 mg of carbetocin or pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 7)

The method of claim 7, wherein the method comprises administering a daily dose of 10 mg of carbetocin.

### Claim 13 (depends on 2)

The method of claim 2, wherein the method comprises administering a daily dose of 28.8 mg of carbetocin and wherein the composition is administered as an intranasal spray.

### Claim 14 (depends on 2)

The method of claim 2, wherein the method comprises administering a daily dose of about 10 mg of carbetocin or pharmaceutically acceptable salt thereof and wherein the composition is administered as an intranasal spray.

### Claim 15 (depends on 2)

The method of claim 2, wherein the method comprises administering a daily dose of 10 mg of carbetocin and wherein the composition is administered as an intranasal spray.

### Claim 16 (depends on 2)

The method of claim 2, wherein the composition is administered as an intranasal spray.

### Claim 17 (depends on 5)

The method of claim 5, wherein the composition is administered as an intranasal spray.

### Claim 18 (depends on 6)

The method of claim 6, wherein the composition is administered as an intranasal spray.

### Claim 19 (depends on 11)

The method of claim 11, wherein the composition comprises the carbetocin or pharmaceutically acceptable salt thereof dissolved in an aqueous solution.

### Claim 20 (depends on 18)

The method of claim 18, wherein the composition comprises the carbetocin or pharmaceutically acceptable salt thereof dissolved in an aqueous solution.

### Claim 21 (depends on 9)

The method of claim 9, wherein the composition comprises a sodium chloride aqueous solution.

### Claim 22 (depends on 21)

The method of claim 21, wherein the aqueous solution comprises about 0.9 wt % of sodium chloride.

### Claim 23 (depends on 1)

The method of claim 1, wherein the composition is in the form of a powder.